Lee Ainslie Dexcom Inc Transaction History

Maverick Capital LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$110.31 - $140.45 $1.84 Million - $2.34 Million	16,664 New	16,664 $1.89 Million
Q4 2023 Feb 14, 2024	SELL	$75.49 - $124.16 $519,748 - $854,841	-6,885 Reduced 58.54%	4,876 $605,000
Q3 2023 Nov 14, 2023	BUY	$86.06 - $137.93 $1.01 Million - $1.62 Million	11,761 New	11,761 $1.1 Million
Q3 2021 Nov 15, 2021	SELL	$106.71 - $143.18 $22,515 - $30,210	-211 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$80.99 - $107.93 $220,940 - $294,433	-2,728 Reduced 92.82%	211 $90,000
Q1 2021 May 17, 2021	BUY	$84.79 - $104.74 $226,982 - $280,388	2,677 Added 1021.76%	2,939 $1.06 Million
Q4 2020 Feb 16, 2021	SELL	$78.0 - $104.5 $7,800 - $10,450	-100 Reduced 27.62%	262 $97,000
Q3 2020 Nov 16, 2020	BUY	$95.51 - $112.95 $34,574 - $40,887	362 New	362 $149,000

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.